This study looks at ML-007C-MA, a pill for adults aged 18-64 with schizophrenia. Schizophrenia is a mental illness that affects how a person thinks, feels, and acts. The study is in Phase 2, meaning it’s still being tested for safety and how well it works. Participants must stay in the hospital during the study, which checks if ML-007C-MA helps with symptoms like hallucinations or delusions. **Key Points:** - **Study Duration:** Participants must stay in a hospital for the entire study. - **Eligibility:** Participants should have schizophrenia and might need to be hospitalized already. - **Risks:** People with certain other disorders or allergies might not be eligible. Some people can't join, like those with other mental disorders or severe allergies. Participants should not have taken other antipsychotic medications recently and cannot join if they've been in another drug study within 90 days. The study aims to see if ML-007C-MA is better than a placebo (a pill with no medicine) in treating schizophrenia symptoms.